Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boon Cher Goh

Showing results (191-200 of 242) with videos related to

Pageof 25
Sort By:
Theranostics|March 21, 2020
Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitorsTan-Min Chin, Gandhi T K Boopathy, Ellen P S Man, et al.
Journal of Hepatology|May 21, 2008
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinomaHung Huynh, Pierce K H Chow, Nallasivam Palanisamy, et al.
EMBO Molecular Medicine|June 1, 2018
Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancerDana Wai Yi Tsui, Muhammed Murtaza, Alvin Seng Cheong Wong, et al.
Breast Cancer Research and Treatment|December 20, 2021
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancerKritika Yadav, Joline Lim, Joan Choo, et al.
Cancer Letters|January 7, 2018
Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signalingLingzhi Wang, Nicholas Li-Xun Syn, Vinod Vijay Subhash, et al.
Therapeutic Advances in Medical Oncology|June 12, 2025
NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignanciesJoan R Choo, Santhiay Nathan Jeraj, Raghav Sundar, et al.
Plos One|February 6, 2013
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patientsLing-Zhi Wang, Jacqueline Ramírez, Winnie Yeo, et al.
The Lancet. Oncology|September 21, 2010
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyKeith C Bible, Vera J Suman, Julian R Molina, et al.
BMC Medicine|July 11, 2018
Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trialNicholas L Syn, Andrea Li-Ann Wong, Soo-Chin Lee, et al.
Targeted Oncology|April 15, 2023
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological MalignanciesCheng E Chee, Melissa Ooi, Soo-Chin Lee, et al.
Pageof 25

Showing results (191-200 of 242) with videos related to

Sort By:
Pageof 25
Theranostics|March 21, 2020
Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitorsTan-Min Chin, Gandhi T K Boopathy, Ellen P S Man, et al.
Journal of Hepatology|May 21, 2008
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinomaHung Huynh, Pierce K H Chow, Nallasivam Palanisamy, et al.
EMBO Molecular Medicine|June 1, 2018
Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancerDana Wai Yi Tsui, Muhammed Murtaza, Alvin Seng Cheong Wong, et al.
Breast Cancer Research and Treatment|December 20, 2021
Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancerKritika Yadav, Joline Lim, Joan Choo, et al.
Cancer Letters|January 7, 2018
Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signalingLingzhi Wang, Nicholas Li-Xun Syn, Vinod Vijay Subhash, et al.
Therapeutic Advances in Medical Oncology|June 12, 2025
NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignanciesJoan R Choo, Santhiay Nathan Jeraj, Raghav Sundar, et al.
Plos One|February 6, 2013
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patientsLing-Zhi Wang, Jacqueline Ramírez, Winnie Yeo, et al.
The Lancet. Oncology|September 21, 2010
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyKeith C Bible, Vera J Suman, Julian R Molina, et al.
BMC Medicine|July 11, 2018
Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trialNicholas L Syn, Andrea Li-Ann Wong, Soo-Chin Lee, et al.
Targeted Oncology|April 15, 2023
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological MalignanciesCheng E Chee, Melissa Ooi, Soo-Chin Lee, et al.
Pageof 25